keyboard_arrow_up

Global Plasma Fractionation Market Research Report 2019

New Market Research Report on “Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019”adds to ReportsnReports.com.

 Over the last five years, the Plasma Fractionation Market  witnessed tremendous growth, primarily due to the growth in aging population, increasing number of hemophilic patients, rising use of IVIg, and high prevalence of chronic disorders across the globe.

 In this report, the global plasma fractionation market is divided on the basis of product, application, and end user. Based on type of products, the plasma fractionation market is mainly segmented into albumin, immunoglobulins, coagulation factor concentrates, and others. The immunoglobulin segment is further subsegmented into intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and others. Coagulation factor concentrates are subsegmented into factor VIII, factor IX, factor XIII, prothrombin coagulation concentrates, Von Willebrand factor, and fibrinogen concentrates.  The plasma fractionation application market is divided into neurology; hematology; immunology; critical care; and others. Likewise, the major end users analyzed in the plasma fractionation market are hospitals and clinics, clinical research laboratories, and academic institutes.

 Complete report available @ http://www.reportsnreports.com/reports/320632-plasma-fractionation-market-by-product-albumin-immunoglobulin-factor-viii-protease-inhibitors-application-neurology-immunology-hematology-critical-care-by-end-user-hospitals-clinical-research-laboratories-global-forecast-to-2019.html .

The global plasma market is expected to grow at a CAGR of 8.9% during the forecast period of 2014–2019. The market is mainly driven by the growth in aging population, increasing use of IVIg, growing number of hemophilic patients, and increasing diagnosis rate globally. However, the high cost of immunoglobulins and hemophilic drugs, stringent government regulations, and rapid increase in the use of recombinant products as an alternative to plasma-derived coagulation factor concentrates are hampering the growth of this market to a certain extent.

IVIg accounts for the major share of the plasma fractionation market. The increasing use of IVIg in clinical areas such as neurology, hematology, immunology, rheumatology, and dermatology, and its excellent efficacy records are the key factors responsible for the growth of this market segment. In addition, the use of IVIg is being evaluated for a wide range of conditions such as adult respiratory distress syndrome, fibrosis, connective tissue disease, encephalitis, heart failure, and Alzheimer’s disease. Positive results in such conditions would increase the demand for IVIg globally in the near future.

In 2013,, North America contribute the largest share to the global plasma fractionation market, followed by Europe, Asia-Pacific, and RoW. Developed geographies like North America and Europe are likely to grow at a lower CAGR as compared to the Asia-Pacific market, which is expected to witness the fastest growth during the forecast period, largely driven by the increasing aging population, increasing use of immunoglobulins, improved economy, rising number of hemophilic patients, growing use of albumin in China, increased accessibility to healthcare facilities, growth in the overall healthcare industry, and growing awareness of technologically advanced products in these regions.

The global plasma fractionation market is mainly dominated by six players that accounted for around 70% of the global plasma fractionation market in 2013. The major players in the global plasma fractionation market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy), Bio Product Laboratory (U.K.), Sanquin (Netherland), Laboratoire Français du Fractionnement et des Biotechnologies (France), and Biotest (Germany).


Purchase a copy of this report @  http://www.reportsnreports.com/Purchase.aspx?name=320632 .

 Table of Contents

 1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Trends

7 Global Plasma Fractionation Market, By Product

8 Global Plasma Fractionation Market, By Application

9 Global Plasma Fractionation Market, By End User

10 Global Plasma Fractionation Market, By Geography

11 Competitive Landscape

12 Company Profiles
12.1 Baxter International, Inc.

12.2 Octapharma AG

12.3 Biotest

12.4 Csl, Ltd.

12.5 Grifols International SA

12.6 Kedrion S.P.A.

12.7 LFB SA

12.8 Kedrion

12.9 Chinese Biological Products, Inc.

12.10 Shanghai Raas Blood Products Co., Ltd.

 Inquire For Discount (Single User Report Price US $4650) @ http://www.reportsnreports.com/contacts/Discount.aspx?name=320632 .

 About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.